SGAM
TVTX icon

Smith Group Asset Management’s Travere Therapeutics TVTX Stock Holding History

Smith Group Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-364
Closed -$7K – 510
2015
Q3 		$7K Buy
+364
New +$10.8K ﹤0.01% 355

Other funds holding TVTX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Smith Group Asset Management's TVTX Position: Q4 2015 in Review

Smith Group Asset Management sold out of Travere Therapeutics (TVTX) in Q4 2015, closing a stake of 364 shares — an estimated $7K sold.

Smith Group Asset Management first reported a position in TVTX in Q3 2015 and held it in 1 quarter. The position peaked at $7K in Q3 2015. 116 funds tracked by Wall St. Rank hold TVTX as of Q4 2015.

  • Smith Group Asset Management reported no remaining Travere Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Smith Group Asset Management sold 364 Travere Therapeutics shares in Q4 2015, an estimated $7K.
  • Smith Group Asset Management first reported a position in Travere Therapeutics in Q3 2015 and held it in 1 quarter.
  • Smith Group Asset Management's Travere Therapeutics position peaked at $7K in Q3 2015.
  • 116 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2015.

Based on Smith Group Asset Management's 13F filing for Q4 2015, filed 3 Feb 2016.